Strikingly, we found that both the trafficking and dendritic branching defects could be reversed by knockdown of the FTD risk factor TMEM106B, suggesting that reduction of TMEM106B levels may be a broadly applicable therapeutic target for FTD. The gene discussed is TMEM106B; the disease is frontotemporal dementia.